Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer

TL;DR

This paper reviews recent advances in EGFR-targeted therapies for a rare type of lung cancer with EGFR mutations, focusing on treatment outcomes and challenges.

Contribution

A comprehensive review of EGFR-targeted therapies specifically for EGFR-mutated squamous cell lung cancer.

Findings

EGFR mutations are rare in squamous cell lung cancer compared to adenocarcinoma.

EGFR-TKIs show some efficacy in EGFR-mutated squamous cell lung cancer patients.

More research is needed to improve treatment outcomes for this rare subgroup.

Abstract

非小细胞肺癌（non-small cell lung cancer, NSCLC）是我国常见的肿瘤之一，肺鳞癌是NSCLC中除肺腺癌外最常见的组织学亚型。表皮生长因子受体（epidermal growth factor receptor, EGFR）是肺癌的驱动基因之一，相比肺腺癌，肺鳞癌中EGFR的突变率很低。针对EGFR的靶向治疗在肺腺癌中已经取得了重大进展，而在肺鳞癌中的进展相对缓慢。本文对近年EGFR突变肺鳞癌分子靶向治疗的相关研究进行综述，总结出EGFR-酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）在肺鳞癌中的疗效，旨在为EGFR突变肺鳞癌患者的治疗提供参考。

Select randomized trials of the EGFR mutation rate and mutation type in squamous cell lung cancer

Efficacy of the EGFR-TKIs in squamous cell lung cancer harboring EGFR mutation